Introduction
============

Depression occurs in about 40%--45% of patients with Parkinson's disease (PD) and reduces both the subjective and objective quality of life independent of motor deficits ([@b6]; [@b13]). Depressive symptoms precede those of motor function in 12%--37% of patients with PD ([@b27]). The pathological feature of PD reveals degeneration of dopaminergic neurons in the striato-nigral system. In addition, the limbic system is also involved in PD ([@b15]). Pramipexole (PPX), D~2~/D~3~ receptor agonist acts on D~3~ versus D~2~ receptors in the regions of the brain that play a key role in the etiology of depression ([@b18]). These mechanisms could explain the effectiveness of PPX on depression in animal experiments ([@b29]; [@b17]) and in patients with major depressive disorder ([@b26]; [@b5]).

Recent European studies show that PPX treatment is beneficial for patients with depression and PD and PPX is more effective on depression in PD as compared with sertraline, an antidepressant ([@b22]; [@b3]). Furthermore, patients with refractory bipolar depression were treated with PPX as add-on therapy to various mood stabilizers ([@b10]; [@b31]; [@b1]).

Thus, the antidepressant effect of PPX in patients with a major depressive disorder has already been studied and PPX seems to be more powerful compared with other ergoline preparations such as bromocriptine, pergolide, and cabelgoline ([@b4]; [@b21]; [@b2]; [@b22]). In this paper we studied how PPX treatment influences depressions and motor scales in PD patients.

Materials and methods
=====================

All patients underwent neurological evaluation. We included patients with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria ([@b7]), and obtained informed consent. The duration of the trial was from March 1st to July 31st 2006. In this prospective, observational, open study, patients with moderate and severe depressive episode defined according to the 10th revision of the International Classification of Diseases were excluded for administration of PPX. In an open study of PPX as an add-on to L-dopa therapy or single administration, PPX was started at 0.125 mg/day and daily doses were increased to 1.5 mg/day. Patients on L-dopa therapy continued to take the same dosage of levodopa which was kept fixed during the study. At 3 months after PPX treatment, patients were re-evaluated. Hamilton Depression Rating Scale (HAM-D) ([@b11]), Unified Parkinson's Disease Rating Scale (UPDRS) III ([@b8]), Hoehn and Yahr (H&Y) stage ([@b12]), and freezing of gait questionnaire (FOGQ) ([@b9]) were compared in patients before and after PPX treatment. Statistical analysis used Wilcoxon signed rank test, Kruskal Wallis test, with SPSS for Windows version 13.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Initially 36 PD outpatients without dementia were entered. A total of 31 patients (16 women and 15 men) were eligible for this trial. The clinical background of 31 patients (16 women and 15 men) is shown in [Table 1](#tbl1){ref-type="table"}. Drop-outs due to adverse events occurred in 3 patients (nausea, aggravation of dyskinesia), but all were not serious, and 2 patients moved to another town. The mean age (SD) was 71.2 (8.3) years (70.9 \[8.6\] in women and 71.4 \[8.2\] in men). The mean disease duration (SD) was 4.4 (7.3) years (4.0 \[3.9\] in women and 4.7 \[3.6\] in men). All were able to walk independently (H&Y stage II or III). Twenty-nine patients received L-dopa. Two patients had PPX alone. None were treated with any antidepressants. Changes of neurological evaluation were shown in [Table 2](#tbl2){ref-type="table"}. After PPX administration, HAM-D score was declined. Motor function scores were also significantly improved. There were no statistical correlations among HAM-D, UPDRS III, H&Y stage, and FOGQ.

###### 

Clinical background of patients

                                Total          Women           Men
  ----------------------------- -------------- --------------- --------------
  Age (years)                   71.2 (8.3)     70.9 (8.6)      71.4 (8.2)
  Duration of disease (years)   4.4 (7.3)      4.0 (3.9)       4.7 (3.6)
  H&Y stage                     2.5 (0.6)      2.5 (0.7)       2.5 (0.5)
  L-dopa doses (mg/day)         217.7 (91.8)   190.6 (100.4)   246.7 (74.3)
  Pramipexole doses (mg/day)    1.1 (0.5)      1.1 (0.5)       1.1 (0.5)

**Notes:** Data are shown as mean (SD).

###### 

Results of depression scale and motor function

                     Baseline      Endpoint
  ------------------ ------------- ---------------------------------------------
  HAM-D              11.7 (6.1)    7.5 (5.4)[\*](#tf2-2){ref-type="table-fn"}
  H&Y stage          2.5 (0.6)     2.1 (1.1)[\*](#tf2-2){ref-type="table-fn"}
  UPDRS III          26.8 (6.2)    20.6 (7.0)[\*](#tf2-2){ref-type="table-fn"}
  Freezing index A   12.1 (11.1)   10.0 (9.2)[\*](#tf2-2){ref-type="table-fn"}
  Freezing index B   5.4 (5.3)     4.2 (4.1)[\*](#tf2-2){ref-type="table-fn"}

**Notes:** Data are shown as mean (SD);

P\< 0.01 by Wilcoxon signed rank test between baseline and endpoint. There were no statistical significances of HAM-D score and other motor scales.

Discussion
==========

We excluded patients with moderate and severe depressive episode. PPX doses used were lower than 1.5 mg/day. Those relative low doses of PPX improved HAM-D score significantly. In relationship between other dopamine agonists and mental changes, bromocriptine worsened psychotic symptoms in patients suffering from schizophrenia, other psychotic disorders, or psychotic depression ([@b20]). Cabergoline can be used similarly to bromocriptine in PD, and only a few reports discussed the efficacy of use in psychotic symptoms ([@b2]). Pergolide is well used in PD, but this dopamine agonist is reported to have no efficacy on depression in PD patients by national multicenter prospective randomized studies ([@b22]). In contrast, ropinirole, which is a nonergot dopamine agonist, as well as PPX showed an antidepressant effect, but no reports showed a comparison of antidepressant efficiency between ropinirole and PPX ([@b19]).

PPX had significantly improved not only depressive parkinsonian patients but also bipolar depression ([@b5]; [@b10]; [@b31]). PPX was well tolerated and was significantly more effective in reducing severity of depression and increasing numbers of responders ([@b10]; [@b31]). These effects may relate to PPX's preference for D~3~ versus D~2~ receptors and neurotrophic properties. Furthermore, D~3~ receptors may have an anatomic distribution which plays an important role in neuronal circuits implicated in depressive states.

According to a detailed survey of antidepressant drugs in PD by the Parkinson Study Group in the USA ([@b23]), the administration of selective serotonin reuptake inhibitors (SSRI) usually serves as the first-choice treatment.

[@b5] reported that PPX for patients with major depression at the 1.0 mg per day dose had significantly improvement over baseline compared to the placebo measure of the HAM-D, Montgomery-Asberg Depression Rating Scale, and Clinician's Global Impressions -- Severity of Illness scale, and the most obvious improvement was seen in the PPX 5.0 mg group, although a substantial dropout rate increased ([@b5]). A recent European study reported that PPX is more effective on depression in PD as compared with the antidepressant sertraline ([@b3]).

In the present study, the HAM-D score was reduced during treatment with PPX and those antidepressant effects did not depend on motor function scale. Previous European experience ([@b16]) and our studies suggest that PPX has benefits for depressive symptoms in PD patients. These results support that the original serotonergic and noradrenergic hypotheses do not fully account for the neurobiology of depression or mechanism of action of effective antidepressants. [@b24] found lower cerebrospinal fluid homovanillic acid (HVA) which was known as dopamine metabolite in depressed subjects than in normal subjects. Also, direct measurement of brain monoamine metabolites from the internal jugular vein of treatment-resistant depressed patients revealed low HVA levels that were highly correlated with illness severity ([@b14]).

Thus, these results support the monoaminergic theories of depression, which hold that dysregulation of systems involving dopamine, in addition to serotonin and norepinephrine, may be involved in major depression. The mechanism of action of currently available antidepressants is to re-equilibrate one or more neurotransmitter systems and restore relative efficiency at one or more synaptic sites, such as by altering postsynaptic receptor sensitivity ([@b25]; [@b30]). It is believed that PPX acts as a direct agonist at the postsynaptic receptor, thereby relieving some symptoms of depression.

Since the HAM-D score and motor function were improved after administration of PPX, and there was no correlation between HAM-D and motor functions, this indicates improvement of HAM-D score was not due to an improvement in motor functions.

We conclude that PPX is a useful strategy in improving of depressive state in PD. Further long-term study of PPX is needed to determine whether this dopamine agonist can prevent upcoming depression in PD.
